Instruction for use: Eltacin

Trade name of the drug – Eltacin

International nonproprietary name Glycine + Glutamic acid+ Cystine

Eltacin enhances the activity of the heart muscle, increases the physical tolerance. It also normalizes the oxidation-reduction processes and improves the use of oxygen in tissues..

Pharmacotherapeutic group: Antioxidant drug

ATC code: C01EX

Pharmacological properties:

Eltacin contains the mix of nonessential amino acids: Glycine, L-glutamic acid and L-cystine, which are act as a metabolic regulator: increase the intracellular level of glutathione and activity of glutathione-dependent enzymes, normalize oxidation-reduction processes and oxygen utilization in tissues; as a result, the drug is able to:

have an antioxidant (decreasing level of free radicals, peroxide compounds and malondialdehyde) and anti-hypoxic (increasing organism resistance to hypoxia, intensifying the ATP synthesis) effect;

enhance the myocardial contractility;

enhance physical tolerance;

enhance life quality of patients with heart failure (increasing the social integration, improving psycho-emotional state);

speed up recovery of working efficiency after strenuous exercise in children.

Pharmacological properties:

Eltacin contains the mix of nonessential amino acids: Glycine, L-glutamic acid and L-cystine, which are act as a metabolic regulator: increase the intracellular level of glutathione and activity of glutathione-dependent enzymes, normalize oxidation-reduction processes and oxygen utilization in tissues; as a result, the drug is able to:

have an antioxidant (decreasing level of free radicals, peroxide compounds and malondialdehyde) and anti-hypoxic (increasing organism resistance to hypoxia, intensifying the ATP synthesis) effect;

enhance the myocardial contractility;

enhance physical tolerance;

enhance life quality of patients with heart failure (increasing the social integration, improving psycho-emotional state);

speed up recovery of working efficiency after strenuous exercise in children.

Indications

Chronic heart failure (I-III NYHA functional classes, on background of basic therapy) in adults;

chronic heart failure (I-II NYHA functional classes, on background of basic therapy) in children of 12-18 years;

vegetative dysfunction syndrome in children of 12-18 years;

prevention of chronic overexertion and recovery after strenuous exercise whilst sports activities in children of 11-15 years.

Contraindications

Individual hypersensitivity to the drug, age under 11 (efficiency and safety are not determined).

Pregnancy and lactation.

Clinical trials of Eltacin during pregnancy and lactation were not conducted. Not recommended to use during pregnancy and lactation.

Eltacin Dosage and administration:

Sublingually. It also possible to chew the tablet and place it under the tongue till it completely dissolve.

Chronic heart failure (I-III NYHA functional classes) in adults: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Chronic heart failure (I-II NYHA functional classes) in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Vegetative dysfunction syndrome in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Prevention of chronic overexertion in children of 11-15 years: 1 tablet 2 times a day for 2-3 weeks.

Recovery after strenuous exercise whilst sports activities in children of 11-15 years: 1 tablet 3 times a day for 2 weeks.

Adverse reactions

Allergic reactions are possible.

Overdosage

No cases of overdose occured.

Drug interactions

There is no information about drug interactions.

Precautions

It is possible to take Eltacin® together with angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, aldosterone antagonists, organic nitrates, and calcium channel-blocking agents.

Dosage form

70 mg + 70 mg + 70 mg sublingual tablets.

Blister with 30 tablets in cardboard pack together with the patient information leaflet.

Storage conditions

Store in a dry place at a temperature under 25 °C, protect from light.

Keep out of the reach of children.

Shelf life

3 years. Do not use after labeled expiration date.

Prescription status

No prescription required.